|
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical research trials and Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma. Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma  Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
For Condition: recurrent adult diffuse large cell lymphoma
Status: Suspended
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Randomized phase II trial to study the effectiveness of epratuzumab in treating patients who have non-Hodgkin's lymphoma.
Details: OBJECTIVES: - Determine the response rate of patients with diffuse large B-cell non-Hodgkin's lymphoma treated with epratuzumab. - Determine the toxicity of this drug in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms. - Arm I: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 4 weeks. - Arm II: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 8 weeks. - Arm III: Patients receive high-dose epratuzumab IV over 1 hour once weekly for 4 weeks. Patients are followed every 3 months for 2 years and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 150 patients (50 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL) - Relapsed or refractory after at least 1 regimen of standard therapy - Prior therapy may include high-dose chemotherapy with autologous stem cell transplantation (ASCT) or immunotherapy - Bidimensionally measurable disease - At least 1 lesion at least 1.5 cm by CT scan - No primary or secondary CNS lymphoma - No HIV-related lymphoma - No known or suspected transformed lymphoma (prior or concurrent) - No bulky disease (i.e., any single mass greater than 10.0 cm) - No pleural effusion with positive cytology for lymphoma - Most recent pathology specimen available for collection - No rapid disease progression or symptoms that indicate disease progression requiring rapid intervention within the past 2 weeks (e.g., severe shortness of breath, severe pain, or gastrointestinal or genitourinary obstruction) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 4 months Hematopoietic - Absolute neutrophil count at least 1,000/mm3 - Platelet count at least 50,000/mm3 (transfusion independent) - Hemoglobin at least 9.0 g/dL Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN) - AST and ALT less than 5 times ULN - Hepatitis B surface antigen negative - Hepatitis C negative Renal - Creatinine no greater than 2 times ULN Other - HIV negative - No other primary malignancy within the past 3 years except squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or stage I prostate cancer - No other serious nonmalignant condition that would preclude study - No serious infection - No known human antichimeric antibodies or human antihuman antibody positivity - No type 1 hypersensitivity or anaphylactic reactions to murine proteins - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 6 months after study PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 4 weeks since prior immunotherapy (unless clearly progressing) - At least 12 weeks since prior ASCT Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy (unless clearly progressing) Endocrine therapy - Not specified Radiotherapy - No prior radioimmunotherapy Surgery - At least 4 weeks since prior major surgery (unless patient has fully recovered) Other - At least 30 days since prior enrollment in clinical trials involving investigational devices or drugs - No concurrent enrollment in other clinical trials involving investigational devices or drugs - No concurrent investigational agents for disease other than NHL
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ChristosEmmanouilides, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000069484; NCI-G02-2094,UCLA-0201056,AMGEN-AMG-412-159
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042913
Other Recurrent Adult Diffuse Large Cell Lymphoma Studies:
1. Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
2. Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
3. Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
4. Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
5. Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Related Studies:
Other recurrent adult diffuse large cell lymphoma Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|
